{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:29:22Z","timestamp":1785774562585,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jdiacomp.2025.109214","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:37:58Z","timestamp":1762360678000},"page":"109214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-na\u00efve type 2 diabetes: The EMPA-FIT study"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-1671","authenticated-orcid":false,"given":"Soo","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghyun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yeon","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-8412","authenticated-orcid":false,"given":"Sungrae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109214_bb0005","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","article-title":"Is glycemic control improving in U.S. adults?","volume":"31","author":"Hoerger","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diabet.2018.07.005","article-title":"Metformin misuse in chronic kidney disease","volume":"46","author":"Coliche","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0020","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-025-01170-4","article-title":"Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors","author":"Lee","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0030","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0035","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-024-03483-z","article-title":"Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","volume":"22","author":"Sohn","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-023-01877-6","article-title":"Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study","volume":"22","author":"Sohn","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Improving global outcomes diabetes Work G. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Disease","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0060","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4093\/dmj.2020.0257","article-title":"Time in range from continuous glucose monitoring: a novel metric for glycemic control","volume":"44","author":"Yoo","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4093\/dmj.2019.0121","article-title":"Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications","volume":"43","author":"Cappon","year":"2019","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","article-title":"Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial","volume":"8","author":"Haak","year":"2017","journal-title":"Diab Ther"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s13300-019-0619-1","article-title":"A view beyond HbA1c: role of continuous glucose monitoring","volume":"10","author":"Chehregosha","year":"2019","journal-title":"Diab Ther"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1507\/endocrj.EJ22-0330","article-title":"The METRO study: a retrospective analysis of the efficacy of metformin for type 2 diabetes in Japan","volume":"70","author":"Harada","year":"2023","journal-title":"Endocr J"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70055","article-title":"Non-linear dose-response relationship for metformin in Japanese patients with type 2 diabetes: analysis of irregular longitudinal data by interpretable machine learning models","volume":"13","author":"Akimoto","year":"2025","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diab.19.9.644","article-title":"Mean amplitude of glycemic excursions, a measure of diabetic instability","volume":"19","author":"Service FJ","year":"1970","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0095","article-title":"How to measure glycemic variability? a literature review","volume":"60","author":"Lazar","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0100","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2147\/DMSO.S418224","article-title":"Correlation between blood glucose indexes generated by the flash glucose monitoring system and diabetic vascular complications","volume":"16","author":"Sheng","year":"2023","journal-title":"Diab Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.666008","article-title":"CGMS and glycemic variability, relevance in clinical research to evaluate interventions in T2D, a literature review","volume":"12","author":"Breyton","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.jdiacomp.2025.109214_bb0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/dia.2024.0404","article-title":"The virtual DCCT: adding continuous glucose monitoring to a landmark clinical trial for prediction of microvascular complications","volume":"27","author":"Kovatchev","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004841","article-title":"Effects of the mean amplitude of glycemic excursions and vascular endothelial dysfunction on cardiovascular events in nondiabetic patients with coronary artery disease","volume":"6","author":"Akasaka","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12933-020-01147-9","article-title":"Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial","volume":"19","author":"Ceriello","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155791","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"153","author":"Popovic","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0130","article-title":"Comparative effectiveness of oral hypoglycemic agents for glycemic control and glycemic variability in patients with type 2 diabetes mellitus: using flash glucose monitoring","volume":"21","author":"Venkatachalapathy","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4093\/dmj.2019.0203","article-title":"Effect of dapagliflozin as an add-on therapy to insulin on the glycemic variability in subjects with Type 2 Diabetes Mellitus (DIVE): a multicenter, placebo-controlled, double-blind, randomized study","volume":"45","author":"Lee","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0155","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/dom.15056","article-title":"Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study","volume":"25","author":"Kang","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3803\/EnM.2020.35.2.329","article-title":"Glycemic efficacy and metabolic consequences of an empagliflozin add-on versus conventional dose-increasing strategy in patients with type 2 diabetes inadequately controlled by metformin and sulfonylurea","volume":"35","author":"Shin","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0170","doi-asserted-by":"crossref","first-page":"32887","DOI":"10.1038\/srep32887","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor increases circulating zinc-Alpha2-glycoprotein levels in patients with type 2 diabetes","volume":"6","author":"Liao","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease","volume":"33","author":"Moon","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0180","doi-asserted-by":"crossref","first-page":"39884","DOI":"10.1038\/srep39884","article-title":"Soluble uric acid activates the NLRP3 inflammasome","volume":"7","author":"Braga","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0185","doi-asserted-by":"crossref","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0195","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.2337\/dc21-1668","article-title":"Effect of dapagliflozin on hematocrit in patients with type 2 diabetes at high cardiovascular risk: observations from DECLARE-TIMI 58","volume":"45","author":"Kolkailah","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0200","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11255-021-02943-2","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis","volume":"54","author":"Kanbay","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0205","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2337\/dc20-0456","article-title":"Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0210","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0215","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2337\/dc20-1104","article-title":"Risk of anemia with metformin use in Type 2 diabetes: a MASTERMIND study","volume":"43","author":"Donnelly","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109214_bb0220","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","year":"2024","journal-title":"Nat Rev Dis Primers"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T12:01:59Z","timestamp":1766232119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1056872725002673"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109214","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-na\u00efve type 2 diabetes: The EMPA-FIT study","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025","name":"copyright","label":"Copyright"}],"article-number":"109214"}}